"Merck, the New Jersey drug-maker, plans a counter-offensive in the escalating battle over Vioxx, the Financial Times reported Monday.
"The company plans to produce internal documents and e-mails to rebut allegations it tried to protect annual sales of $2.5 billion with a five-year campaign of deceitful science and marketing." [Forbes.com]
